The preliminary clinical phase 1 trial of STING agonist (MK-1454) in solid tumors and lymphomas has shown only a modest clinical response using single-agent treatment with no marked activity seen, and the co-administration of it with ICIs in advanced cancers showed only partial responses [80]. The gene discussed is STING1; the disease is cancer.